Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas

Spych,Michal; Gottwald,Leszek; Jesień‑Lewandowicz,Emilia; Sztajer,Sławomir; Fijuth,Jacek

doi:10.3892/ol.2012.759

Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas

Authors:
- Michal Spych
- Leszek Gottwald
- Emilia Jesień‑Lewandowicz
- Sławomir Sztajer
- Jacek Fijuth
View Affiliations

Affiliations: Radiotherapy Department, Chair of Oncology, Medical University of Lodz, Lodz, Poland, Palliative Care Unit, Chair of Oncology, Medical University of Lodz, Lodz, Poland, Radiology Department, Medical University of Lodz, Lodz, Poland
Published online on: June 14, 2012 https://doi.org/10.3892/ol.2012.759
Pages: 455-460

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to the favorable natural history in patients with low-grade gliomas (LGGs), there is no consensus on the treatment strategy following maximal safe surgical resection. A number of studies have been conducted to identify prognostic factors in patients treated for LGG. The present study evaluated the treatment outcomes as well as prognostic factors and their impact on overall survival (OS) and disease-free survival (DFS). We retrospectively reviewed 30 consecutive patients treated for LGG at the Department of Radiotherapy from February 2008 to July 2011. The patients underwent surgical intervention and postoperative radiotherapy. The response to radiotherapy was evaluated from six to eight weeks after the end of treatment using MRI analysis. Kaplan-Maier analysis was used for OS and DFS estimation. The endpoint was mortality as a result of any cause. Within a median follow-up of 21.8 months, 9 patients (30%) with disease progression were reported. The two- and five-year DFS and OS was 85.2 and 68.3% for DFS, and 84.3 and 63.4% for OS, respectively. The response to radiotherapy, evaluated in an MRI study, was found to be highly correlated with OS (p<0.0001). We also observed a significantly higher OS in patients with disease progression treated with salvage chemotherapy after the end of radiotherapy (p=0.08). Improved outcome among patients with LGG may be predicted by response to radiotherapy evaluated by MRI following termination of treatment.

View Figures

View References

1	Berger MS, Deliganis AV, Dobbins J and Keles GE: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 74:1784–1791. 1994. View Article : Google Scholar : PubMed/NCBI
2	Claus EB, Horlacher A, Hsu L, et al: Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 103:1227–1233. 2005. View Article : Google Scholar : PubMed/NCBI
3	Leighton C, Fisher B, Bauman G, et al: Supratentorial low-grade in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 15:1294–1301. 1997.PubMed/NCBI
4	Van den Bent MJ, Afra D, de Witte O, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomized trial. Lancet. 366:985–990. 2005.PubMed/NCBI
5	Karim AB, Maat B, Hatlevoll R, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 36:549–556. 1996. View Article : Google Scholar : PubMed/NCBI
6	Shaw E, Arusell R, Scheithauer B, et al: Prospective randomized trial of low versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 20:2267–2276. 2002. View Article : Google Scholar
7	Lote K, Egeland T, Hager B, et al: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 15:3129–3140. 1997.PubMed/NCBI
8	Janny P, Cure H, Mohr M, et al: Low grade supratentorial astrocytomas: management and prognostic factors. Cancer. 73:1937–1945. 1994. View Article : Google Scholar : PubMed/NCBI
9	Pignatti F, van den Bent M, Curran D, et al: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 20:2076–2084. 2002. View Article : Google Scholar : PubMed/NCBI
10	Nicolato A, Gerosa MA, Fina P, Iuzzolino P, Giorgiutti F and Bricolo A: Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated patients. Neurosurgery. 44:208–223. 1995.
11	Soffietti R, Chiò A, Giordana MT, Vasario E and Schiffer D: Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery. 24:686–692. 1989. View Article : Google Scholar : PubMed/NCBI
12	Shibamoto Y, Kitakabu Y, Takahashi M, et al: Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer. 72:190–195. 1993. View Article : Google Scholar
13	Vecht CJ: Effect of age on treatment decisions in low-grade glioma. J Neurol Neurosurg Psychiatry. 56:1259–1264. 1993. View Article : Google Scholar : PubMed/NCBI
14	van Veelen ML, Avezaat CJ, Kros JM, van Putten W and Vecht C: Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psych. 64:581–587. 1998.PubMed/NCBI
15	Bauman G, Fischer B, Walting C, Cairncross JG and Macdonald D: Adult Supratentorial low-grade gliomas: long experience at a single institution. J Radiat Oncol Biol Phys. 75:1401–1407. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bauman G, Pahapill P, Macdonald D, Fisher B, Leighton C and Cairncross G: Low grade glioma: a measuring radiographic response to radiotherapy. Can J Neurol Sci. 26:18–22. 1999.PubMed/NCBI
17	Eyre HJ, Crowley JJ, Townsend JJ, et al: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg. 78:909–914. 1993. View Article : Google Scholar : PubMed/NCBI
18	Lunsford LD, Somaza S, Kondziolka D and Flickenger JC: Survival after stereotactic biopsy and radiation of cerebral non pilocytic astrocytoma. J Neurosurg. 82:523–529. 1995. View Article : Google Scholar : PubMed/NCBI
19	Shaw EG, Berkey B, Coons SW, et al: Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG). ASCO 2006 Annual Meeting Proceedings. J Clin Oncol. 24:Abstr 1500. 2006.
20	Quinn JA, Reardon DA, Friedman AH, et al: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 21:646–651. 2003. View Article : Google Scholar : PubMed/NCBI
21	van den Bent MJ, Taphoorn MJ, Brandes AA, et al: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group study 26971. J Clin Oncol. 21:2525–2528. 2003.PubMed/NCBI
22	van den Bent MJ, Chinot O, Boogerd W, et al: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol. 14:599–602. 2003.
23	Hoang-Xuan K, Capelle L, Kujas M, et al: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 22:3133–3138. 2004. View Article : Google Scholar : PubMed/NCBI
24	Buckner JC, Gesme D Jr, O’Fallon JR, et al: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 21:251–255. 2003. View Article : Google Scholar
25	Brada M, Viviers L, Abson C, et al: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 14:1715–1721. 2003. View Article : Google Scholar : PubMed/NCBI
26	Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, et al: Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 14:1722–1726. 2003. View Article : Google Scholar : PubMed/NCBI
27	Stege EM, Kros JM, de Bruin HG, et al: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer. 103:802–809. 2005. View Article : Google Scholar : PubMed/NCBI
28	Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P and Barnett G: Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol. 61:267–273. 2003. View Article : Google Scholar : PubMed/NCBI
29	Jenkins RB, Blair H, Ballman KV, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66:9852–9861. 2006. View Article : Google Scholar : PubMed/NCBI